Sionna Therapeutics, Inc. announced on October 1, 2025, that it will present data at the 2025 North American Cystic Fibrosis Conference (NACFC), scheduled for October 22-25, 2025, in Seattle, Washington. The presentations will include details on the safety, tolerability, and pharmacokinetics of its novel NBD1 stabilizers, SION-719 and SION-451.
Dr. Jason H. Maley, Senior Director of Clinical Development at Sionna Therapeutics, will present findings from two Phase 1 first-in-human studies for SION-719 and SION-451. This presentation will occur during the 'Cutting-edge Clinical Trials: Insights & Updates Workshop' on October 24, 2025.
Additionally, preclinical data will be presented by Dr. Gregory Hurlburt, Co-Founder and Senior Vice President, Discovery Research. This presentation will detail how small molecule stabilizers of CFTR NBD1 can extend the half-life of the apical glycoform of F508del-CFTR to match that of wild-type CFTR.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.